DDI-DrugBank.d608.s0 >> The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers. >> 24-31,75-82,89-96
DDI-DrugBank.d608.s1 >> However, increased prothrombin time and bleeding have been reported in patients on concomitant TOLECTIN and warfarin therapy. >> 95-102,108-115
DDI-DrugBank.d608.s2 >> Therefore, caution should be exercised when administering TOLECTIN to patients on anticoagulants. >> 58-65,82-95
DDI-DrugBank.d608.s3 >> In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. >> 55-67,72-78,133-140,149-167
DDI-DrugBank.d608.s4 >> Caution should be used if TOLECTIN is administered concomitantly with methotrexate. >> 26-33,70-81
DDI-DrugBank.d608.s5 >> TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. >> 0-7,19-54,110-121,178-189
DDI-DrugBank.d608.s6 >> Laboratory Tests Because serious GI tract ulceration and bleeding can occur without warning symptoms, physicians should follow chronically treated patients for the signs and symptoms of ulceration and bleeding and should inform them of the importance of this follow-up.
